This interview with a US-based key opinion leader (KOL) offers insights into current treatment practices, prescribing behaviors, and late-phase pipeline therapies in Idiopathic Pulmonary Fibrosis (IPF). The discussion highlights disease progression, diagnostic pathways, and challenges in treatment adherence, particularly due to limited efficacy and tolerability of current antifibrotic therapies. Additional topics include treatment sequencing, transplant considerations, and key unmet needs in IPF management.

Currently approved antifibrotic therapies such as Nintedanib, Pirfenidone, and Jascayd remain the mainstay of care, though their clinical benefit is considered modest and often limited by tolerability issues. The expert emphasized that while these agents slow disease progression, they do not halt or reverse fibrosis, and real-world outcomes often fall short of clinical trial data. The expert also discussed the potential of several investigational therapies currently in early- and mid-stage development.

This interview was conducted on February 09, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.